Clinical Trial Search

Primary: RAI (Radioactive Iodine) Uptake and Tg (Thyroglobulin) Level Compared Pre and Post- Valproic Treatment — 6; 1; 1; 0 Participants

Primary: Change in Clinical Activity Score (CAS) — -1.2; -1.5 units on a scale — p=0.73

Primary: Restoration of Radioiodine Uptake in Metastatic Lesions as Demonstrated by Diagnostic Whole-body Scanning After Decitabine Administration — 0 participants

Primary: Executive Function — 7.9; 7.5; 8.8 units on a scale

Primary: Percentage of Participants With Transient Hypoparathyroidism, as Defined by a Day 1 Serum Parathyroid Hormone (PTH) Level of < 10 pg/ml — 24.1; 33.3 percentage of…

Primary: Maximum Tolerated Dose (MTD) [Phase I Dose Escalation] — 5 mg

Primary: Change in Tumor Size — 4.7 cm

Primary: TSH Response to TRH — 11.47 mcIU/mL

Primary: Response at 6 Months — 7; 2 Participants — p=0.0787

Primary: The Rate of Successful Thyroid Ablation as Defined by Negative Recombinant Human Thyrotropin (rhTSH) Stimulated Radioiodine Whole Body Scan (RAI WBS) at 1 Year. — 10; 10…

Primary: Thyroid Stimulating Hormone as Primary Endpoint Measured at Initiation of Study, After 8 Weeks of One Drug, and Then 8 Weeks After the Second Drug. — 2.455; 2.131…

Primary: Number of Participants With Any Treatment-emergent Adverse Event (TEAE), Serious AE (SAE), Treatment-related Adverse Event (AE), and Death During the 6-week Treatment…

Primary: Insulin-mediated Glucose Disposal Rate at Levothyroxine Treatment Phase — 7.26 mg/kg/min

Primary: TSH Area Under the Curve — 267.8; 266.2 μIU*min/mL

Primary: Total Body Glucose Disposal in the Fasting State — 21.47 μmol/kg LBM (Lean Body Mass)/min